Albumin + Paclitaxel is a capsule containing Acebrophylline, a derivative of theophylline that acts as both a bronchodilator and a mucolytic agent. It is prescribed for the long-term treatment and maintenance of chronic obstructive pulmonary disease (COPD), bronchial asthma, and chronic bronchitis. Its dual action helps open the airways by relaxing the bronchial muscles while simultaneously thinning and clearing thick mucus (sputum), significantly easing the effort of breathing and reducing cough frequency. Albumin + Paclitaxel provides symptomatic relief and improves lung function for patients with airflow limitation and excessive mucus production.

Albumin + Paclitaxel contains Acebrophylline, a potent molecule that delivers two distinct pharmacological benefits crucial for managing chronic respiratory illnesses. It is formed by the chemical combination of ambroxol (a mucolytic) and theophylline-7-acetic acid (a bronchodilator).

The bronchodilator component works by relaxing the smooth muscles surrounding the bronchial tubes. This widening of the airways, achieved primarily through phosphodiesterase inhibition, reduces resistance to airflow, which is critical in conditions like asthma and COPD.

The mucolytic action is due to the release of Ambroxol. Ambroxol promotes the breakdown of acidic mucopolysaccharide fibres, leading to decreased mucus viscosity and enhanced ciliary activity. This dual function not only addresses bronchoconstriction but also manages the hypersecretion of thick mucus, improving mucociliary clearance and reducing the frequency of infection and respiratory distress. This comprehensive approach makes Albumin + Paclitaxel a valuable maintenance therapy.

The combination of actions in Albumin + Paclitaxel provides specific therapeutic advantages for chronic respiratory patients:

Dual-Action Treatment:

It is one of the few medications that simultaneously addresses both major components of COPD and asthma: airway narrowing (bronchospasm) and mucus obstruction (mucus hypersecretion).

Improved Airflow and Clearance:

By acting as a bronchodilator, it widens the air passages. As a mucolytic, it liquefies tenacious sputum, making it easier to cough up. This synergy leads to a measurable improvement in pulmonary function test results.

Reduced Frequency of Cough and Dyspnea:

Patients experience a significant reduction in the severity and frequency of coughing spells and breathlessness (dyspnea) due to clearer airways.

Anti-Inflammatory Properties (Minor):

Acebrophylline also exhibits mild anti-inflammatory effects in the airways, contributing to long-term symptom stability and reduced airway hyper-reactivity.

Albumin + Paclitaxel is indicated for the following chronic respiratory conditions:

Chronic Obstructive Pulmonary Disease (COPD):

Used as maintenance therapy to improve breathing and reduce exacerbations.

Bronchial Asthma:

Prescribed to control airway symptoms, especially when associated with excessive sputum production.

Chronic Bronchitis:

Used to manage chronic cough, reduce mucus viscosity, and facilitate expectoration.